Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 2, 2007, Pages 915-930

  Kaur, Kirandeep ^a   Patel, Sanjay R ^a   Patil, Premanand ^a   Jain, Meenakshi ^a   Khan, Shabana I ^b   Jacob, Melissa R ^b   Ganesan, Shobana ^c   Tekwani, Babu L ^b,c   Jain, Rahul ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

8 Quinolinamines; Antimicrobial; Cytotoxicity; Leishmania; Malaria; Methemoglobin toxicity; Synthesis

Indexed keywords

ANTIINFECTIVE AGENT; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; CHLOROQUINE; METHEMOGLOBIN; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 3 (1H IMIDAZOL 4 YL)PROPANAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 3 (1H INDOL 3 YL)PROPANAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 3 (4 HYDROXYPHENYL)PROPANAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 3 BENZYLSULFANYLPROPANAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 3 HYDROXYPROPIONAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 3 PHENYLPROPANAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 3 SULFANYLPROPANAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 4 METHYLSULFANYLBUTANAMIDE; N1 [4 (4 ETHYL 6 METHOXY 5 PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2 AMINO 5 AMINO(IMINO)METHYLAMINOPENTANAMIDE; N1 [4 (4 ETHYL 6 METHOXY PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2,5 DIAMINOPENTANAMIDE; N1 [4 (4 ETHYL 6 METHOXY PENTYLOXY 8 QUINOLYLAMINO)PENTYL] 2,6 DIAMINOHEXANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 3 (1H IMIDAZOL 4 YL)PROPANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 3 (1H INDOL 3 YL)PROPANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 3 (4 HYDROXYPHENYL)PROPANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 3 BENZYLSULFANYLPROPANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 3 HYDROXYPROPANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 3 PHENYLPROPANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 3 SULFANYLPROPANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 4 METHYLSULFANYLBUTANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2 AMINO 5 AMINO(IMINO)METHYLAMINOPENTANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2,6 DIAMINOHEXANAMIDE; N1 [4 [2 (TERT BUTYL) 6 METHOXY 8 QUINOLYLAMINO]PENTYL] 2,6 DIAMINOPENTANAMIDE; PRIMAQUINE; QUINOLINE DERIVATIVE; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; LEISHMANIA; LEISHMANIA DONOVANI; MALARIA; MAMMAL CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMODIUM; PLASMODIUM FALCIPARUM; PROMASTIGOTE;

AMINOQUINOLINES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; ANTIPARASITIC AGENTS; BACTERIA; CERCOPITHECUS AETHIOPS; ERYTHROCYTES; FUNGI; HUMANS; INDICATORS AND REAGENTS; L-LACTATE DEHYDROGENASE; LEISHMANIA DONOVANI; MAGNETIC RESONANCE SPECTROSCOPY; METHEMOGLOBIN; METHICILLIN RESISTANCE; MICE; MICROBIAL SENSITIVITY TESTS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS;

FUNGI; LEISHMANIA DONOVANI; MAMMALIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 33845340165     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.10.036     Document Type: Article

References (33)

1. World Health Organization, Malaria Fact Sheet, No. 94, 2006; http://www.who.int/mediacentre/factsheets/fs094/en/.
2. World Health Organization, Leishmaniases Fact Sheet, No. 116, 2000; http://www.who.int/mediacentre/factsheets/fs116/en/.
3. Overbye K.M., and Barrett J.F. Drug Discov. Today 10 (2005) 45
4. Neu H.C. Science 257 (1992) 1064
5. Vangapandu S., Jain M., Kaur K., Patil P., Patel S.R., and Jain R. Med. Res. Rev. (2006) 10.1002/med.20062
6. Yeates C. Curr. Opin. Investig. Drugs 3 (2002) 1446
7. Jain M., Khan S.I., Tekwani B.L., Jacob M.R., Singh S., Singh P.P., and Jain R. Bioorg. Med. Chem. 13 (2005) 4458
8. Armer R.E., Barlow J.S., Dutton C.J., Greenway D.H.J., Greenwood S.D.W., Lad N., and Tommasini I. Bioorg. Med. Chem. Lett. 7 (1997) 2585
9. Nodiff E.A. Prog. Med. Chem. 28 (1991) 1
10. Strother A., Allahyari R., Buchholz J., Fraser I.M., and Tilton B.E. Drug Metab. Dispos. 12 (1983) 35
11. Baker J.K., Clark A.M., and McChesney J.D. J. Pharm. Res. 73 (1984) 502
12. Allahyari R., Strother A., Fraser I.M., and Verbiscar A.J. J. Med. Chem. 27 (1984) 407
13. Jain R., Gupta R.C., and Anand N. Indian J. Chem. B (1994) 792
14. Jain M., Vangapandu S., Sachdeva S., Singh S., Singh P.P., Jena G.B., Tikoo K., Ramarao P., Kaul C.L., and Jain R. J. Med. Chem. 47 (2004) 285
15. Vangapandu S., Sachdeva S., Jain M., Singh S., Singh P.P., Kaul C.L., and Jain R. Bioorg. Med. Chem. 11 (2003) 4557
16. Jain R., Jain S., Gupta R.C., Anand N., Dutta G.P., and Puri S.K. Indian J. Chem. 33B (1994) 251
17. Vangapandu S., Sachdeva S., Jain M., Singh S., Singh P.P., Kaul C.L., and Jain R. Bioorg. Med. Chem. 12 (2004) 239
18. Jain M., Vangapandu S., Sachdeva S., and Jain R. Bioorg. Med. Chem. 12 (2004) 1003
19. The l- and d-primaquine exhibit similar antimalarial activities:. Carroll F.I., Berrang B., and Linn C.P. J. Med. Chem. 21 (1978) 326 and drug is used clinically as racemate. In this study, racemic 2 and 3 were used, and attempts were not made to separate diastereoisomers of synthesized 8-quinolinamines 21-33 and 51-63
20. Chu T.H.L.C.K., Yang C.S., Lu X.T., and Chang C.C. Yao Hsueh Hsueh Pao 4 (1956) 197
21. Makler M.T., and Hinrichs D.J. Am. J. Trop. Med. Hyg. 48 (1993) 205
22. Borenfreund E., Babich H., and Martin-Alguacil N. In Vitro Cell Dev. Biol. 26 (1990) 1030
23. Mustafa J., Khan S.I., Ma G., Walker L.A., and Khan I.A. Lipids 39 (2004) 167
24. Fasanmade A.A., and Jusko W.J. Drug Metab. Dispos. 23 (1995) 573
25. Harrison J.H., and Jollow D.J. Mol. Pharmacol. 32 (1987) 423
26. Mikus J., and Steverding D. Parasitol. Int. 48 (2000) 265
27. Ma G., Khan S.I., Jacob M.R., Tekwani B.L., Li Z., Pasco D.S., Walker L.A., and Khan I.A. Antimicrob. Agents Chemother. 48 (2004) 4450
28. Evelyn K.A., and Malloy H.T. J. Biol. Chem. 126 (1938) 655
29. NCCLS, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically M7-A5. National Committee on Clinical Laboratory Standards, 2000, 20.
30. NCCLS, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard M27-A2. National Committee on Clinical Laboratory Standards, 2002, 22.
31. NCCLS, Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, M38-A. National Committee on Clinical Laboratory Standards, 2002, 22.
32. NCCLS, Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actinomycetes; Tentative Standard-Second Edition, M24-T2. National Committee on Clinical Laboratory Standards, 2000, 20.
33. Franzblau S.G., Witzig R.S., McLaughlin J.C., Torres P., Madico G., Hernandez A., Degnan M.T., Cook M.B., Quenzer V.K., Ferguson R.M., and Gilman R.H. J. Clin. Microbiol. 36 (1998) 362